LakeShore Biopharma Co., Ltd

About LakeShore Biopharma Co., Ltd

LakeShore Biopharma (Nasdaq: LSB, formerly Yisheng Biopharma) is a comprehensive biopharmaceutical company listed on Nasdaq, focusing on the production, sales, and R&D of vaccines and biological products for infectious diseases. The company aims to safeguard human health through innovation, striving to become a leading domestic and internationally renowned innovative vaccine company.

Products & Services

Freeze-dried Human Rabies Vaccine (Vero Cell):Main product with cumulative sales exceeding 100 million doses since launch.

PIKA COVID-19 Vaccine:A vaccine candidate in the product pipeline.

PIKA Hepatitis B Vaccine (YS-HBV-001):A vaccine candidate for Hepatitis B.

PIKA Hepatitis B Vaccine (E. coli & Yeast):A variant of Hepatitis B vaccine in development.

PIKA Rabies Vaccine (Human Diploid Cell):A rabies vaccine candidate using human diploid cells.

Specialties

Vaccine Development Infectious Disease Prevention Immunotherapy PIKA Immune Modulation Technology

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Private Placement T: - FT: Private Placement	A: 15000000 MR: - FA: US$15 million FAN: 15000000	D: 2025-07-08 FD: 2025-07-08	1 investors

Private Placement Latest

2025-07-08

$15.0M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

王

王旭

Director and Chief Executive Officer

邵

邵辉

Director, Vice Chairman

余

余睿

Director and Chief Financial Officer

刘

刘媛

Vaccine Research and Development General Manager

冉

冉智元

Marketing General Manager

滕

滕红刚

Production and Manufacturing General Manager

View 7 more team members with Pro

Unlock Full Team Directory

Recent News